Puma Biotechnology out-licenses Nerlynx in Canada

12 January 2019

USA-based Puma Biotechnology (Nasdaq: PBYI) has entered into an exclusive license agreement granting Knight Therapeutics (TSX: GUD) the exclusive right in Canada to commercialize Nerlynx (neratinib), which generated global sales of $52.6 million in the third quarter of 2018.

Puma Biotechnology filed a new drug submission for Nerlynx with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Under the terms of the deal, Knight will be responsible for all commercial activities and future regulatory submissions for Nerlynx in Canada. Puma will receive upfront and milestone payments up to $7.2 million throughout the term of this agreement, as well as double digit royalties on net sales of the drug in Canada.

“Our new agreement with Knight demonstrates our commitment to bringing Nerlynx to patients around the world while continuing to focus our commercial resources on the US market,” stated Alan Auerbach, chief executive officer and president of Puma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK